nach oben

Annals of Hematology

Erschienen in:

01.11.2003 | Review Article

Non-Hodgkin's lymphoma in the elderly

A review with emphasis on elderly patients, geriatric assessment, and future perspectives

verfasst von: E. Maartense, H. C. Kluin-Nelemans, E. M. Noordijk

Erschienen in: Annals of Hematology | Ausgabe 11/2003

Einloggen, um Zugang zu erhalten

Abstract

With rising age the incidence of non-Hodgkin's lymphoma (NHL), together with the fact that the proportion of people older than 65 years in Western populations will double during the next 40 years, poses the challenge to adequately meet the needs of elderly patients. After a general introduction on cancer in the elderly, a review is given concerning aspects of epidemiology and prognostic factors of NHL. Therapeutic strategies, including the use of hematopoietic growth factors, for the elderly with aggressive NHL are discussed. The future role for so-called comprehensive geriatric assessment (CGA) to appropriately determine treatment possibilities is emphasized. Much scientific work has to be performed before the true value of CGA instruments can be acknowledged. Screening instruments are discussed and the role for specially trained oncology nurses in the assessment process is stipulated.

Balducci L, Extermann M (2001) A practical approach to the older patient with cancer. Curr Probl Cancer 25:5-76

Wymenga ANM, Slaets JPJ, Sleijfer DTh (2001) Treatment of cancer in old age, shortcomings and challenges. Neth J Med 59:259–266CrossRefPubMed

Visser O, Coebergh JWW, Dijck JAAM van, Siesling S (eds) (2002) Incidence of cancer in the Netherlands 1998. Vereniging van Integrale Kankercentra, Utrecht

Extermann M, Balducci L, Lyman GH (2000) What threshold for adjuvant therapy in older breast cancer patients? J Clin Oncol 18:1709–1717PubMed

Extermann M, Overcash J, Lyman GH, Parr J, Balducci L (1998) Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 16:1582–1587PubMed

Repetto L, Fratino L, Audisio RA, Venturino A, Gianni W, Vercelli M, Parodi S, Dal Lago D, Gioia F, Monfardini S, Aapro MS, Serraino D, Zagonel V (2002) Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology study. J Clin Oncol 20:494–502CrossRefPubMed

McCorkle R, Strumpf NE, Nuamah IF, Adler DC, Cooley ME, Jepson C, Lusk EJ, Torosian M (2000) A specialized home care intervention improves survival among older post-surgical cancer patients. J Am Geriatr Soc 48:1707–1713PubMed

Dijck JAAM van, Coebergh JWW, Siesling S, Visser O (eds) (2002) Trends of cancer in the Netherlands 1989–1998. Vereniging van Integrale Kankercentra, Utrecht

d'Amore F, Brincker H, Christensen BE, Thorling K, Pedersen M, Lanng Nielsen J, Sandberg E, Pedersen NT, Sørensen E (1992) Non-Hodgkin's lymphoma in the elderly. Ann Oncol 3:379–386PubMed

10.

Krol ADG, Cessie le S, Snijder S, Kluin-Nelemans JC, Kluin PhM, Noordijk EM (2003) Non-Hodgkin's lymphoma in The Netherlands: results from a population-based registry. Leuk Lymphoma 44:451–458PubMed

11.

Maartense E, Hermans J, Kluin-Nelemans JC, Kluin PhM, Deijk van WA, Snijder S, Wijermans PW, Noordijk EM (1998) Elderly patients with non-Hodgkin's lymphoma: population-based results in the Netherlands. Ann Oncol 9:1219–1227

12.

Maartense E, Kluin-Nelemans JC, Cessie le S, Kluin PhM, Snijder S, Noordijk EM (2000) Different age limits for elderly patients with indolent and aggressive non-Hodgkin lymphoma and the role of relative survival with increasing age. Analysis of a population-based non-Hodgkin lymphoma registry. Cancer 89:2667–2676CrossRefPubMed

13.

Cartwright R, Brincker H, Carli PM, Clayden D, Coebergh JW, Jack A, McNally R, Morgan G, Sanjose de S, Tumino R, Vornanen M (1999) The rise in incidence of lymphomas in Europe 1985–1992. Eur J Cancer 35:627–633CrossRefPubMed

14.

Eltom MA, Jemal A, Mbulaiteye SM, Devesa SS, Biggar RJ (2002) Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst 94:1204–1210CrossRefPubMed

15.

Carli PM, Coebergh JWW, Verdecchia A, the EUROCARE Working Group (1998) Variation in survival of adult patients with haematological malignancies in Europe since 1978. Eur J Cancer 34:2253–2263CrossRef

16.

The International non-Hodgkin's Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987–994PubMed

17.

Lopez-Guillermo A, Montserrat E, Bosch F, Terol MJ, Campo E, Rozman C (1994) Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma. J Clin Oncol 12:1343–1348PubMed

18.

Hermans J, Krol ADG, Groningen van K, Kluin PhM, Kluin-Nelemans JC, Kramer MHH, Noordijk EM, Ong F, Wijermans PW (1995) International prognostic index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades. Blood 86:1460–1463PubMed

19.

Bastion Y, Coiffier B (1994) Is the international prognostic index for aggressive lymphoma patients useful for follicular lymphoma patients (editorial)? J Clin Oncol 12:1340–1342PubMed

20.

Leonard RCF, Hayward RL, Prescott RJ, Wang J-X (1991) The identification of discrete prognostic groups in low grade non-Hodgkin's lymphoma. Ann Oncol 2:655–662

21.

Cameron DA, Leonard RCF, Mao J-H, Prescott RJ (1993) Identification of prognostic groups in follicular lymphoma. Leuk Lymphoma 10:89–99PubMed

22.

Romaguera JE, McLaughlin P, North L, Dixon D, Silvermintz KB, Garnsey LA, Velasquez WS, Hagemeister FB, Cabanillas F (1991) Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: a risk model. J Clin Oncol 9:762–769PubMed

23.

Rodriguez J, McLaughlin P, Hagemeister FB, Fayad L, Rodriguez MA, Santiago M, Hess M, Romaguera J, Cabanillas F (1999) Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features. Blood 93:2202–2207PubMed

24.

Decaudin D, Lepage E, Brousse N, Brice P, Harousseau JL, Belhadj K, Tilly H, Michaux L, Chèze S, Coiffier B, Solal-Céligny Ph (1999) Low-grade stage III-IV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients—a study of the Groupe d'Etude des Lymphomes de l' Adulte. J Clin Oncol 17:2499–2505PubMed

25.

Federico M, Vitolo U, Zinzani PL, Chisesi T, Clò V, Bellesi G, Maganoli M, Liberati M, Boccomini C, Niscola P, Pavone V, Cuneo A, Santini G, Brugiatelli M, Baldini L, Rigacci L, Resegotti L (2000) Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Blood 95:783–789PubMed

26.

Maartense E, Cessie le S, Kluin-Nelemans JC, Kluin PhM, Snijder S, Wijermans PW, Noordijk EM (2002) Age-related differences among patients with follicular lymphoma and the importance of prognostic scoring systems: analysis from a population-based non-Hodgkin's lymphoma registry. Ann Oncol 13:1275–1284

27.

The Non-Hodgkin's Lymphoma Classification Project (1997) Effect of age on the characteristics and clinical behavior of non-Hodgkin's lymphoma patients. Ann Oncol 8:973–978

28.

Drillenburg P, Wielenga VJM, Kramer MHH, Krieken van JHJM, Kluin-Nelemans JC, Hermans J, Heisterkamp S, Noordijk EM, Kluin PhM, Pals ST (1999) CD44 expression predicts disease outcome in localized large B-cell lymphoma. Leukemia 13:1448–1455CrossRefPubMed

29.

Shipp MA (1994) Prognostic factors in aggressive non-Hodgkin's lymphoma: who has "high-risk" disease? Blood 83:1165–1173PubMed

30.

Montserrat E (2001) Prognostic factors in aggressive lymphoma: the contribution of novel biological markers. Ann Hematol 80: B42-B44PubMed

31.

Kluin PhM (1994) Bcl-6 in lymphoma—sorting out a wastebasket (editorial)? N Engl J Med 331:116–118CrossRefPubMed

32.

Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) (2001) World Health Organization Classification of tumours. Pathology and genetics of haematopoietic and lymphoid tissues. IARC Press, Lyon

33.

Hermine O, Haioun C, Lepage E, d'Agay MF, Briere J, Lavignac C, Fillet G, Salles G, Marolleau JP, Diebold J, Reyes F, Gaulard Ph (1996) Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Blood 87:265–272PubMed

34.

Hill ME, MacLennan KA, Cunningham DC, Vaughan Hudson B, Burke M, Clarke P, Di Stefano F, Anderson L, Vaughan Hudson G, Mason D, Selby P, Linch DC (1996) Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma; a British National Lymphoma Investigation study. Blood 88:1046–1051PubMed

35.

Kramer MHH, Hermans J, Parker J, Krol ADG, Kluin-Nelemans JC, Haak HL, Groningen van K, Krieken van JHJM, Jong de J, Kluin PhM (1996) Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study. J Clin Oncol 14:2131–2138PubMed

36.

Gascoyne RD, Adomat SA, Krajewski S, Krajewska M, Horsman DE, Tolcher AW, O'Reilly SE, Hoskins P, Coldman AJ, Reed JC, Connors JM (1997) Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 90:244–251PubMed

37.

Kramer MHH, Hermans J, Wijburg E, Philippo K, Geelen E, Krieken van JHJM, Jong de D, Maartense E, Schuuring E, Kluin PhM (1998) Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 92:3152–3162PubMed

38.

Winter JN (1999) Prognostic indicators in diffuse, aggressive non-Hodgkin's lymphomas: regulators of growth fraction and programmed cell death. Semin Oncol 26 [Suppl 14]:26–33

39.

Gascoyne RD (1997) Pathologic prognostic factors in diffuse aggressive non-Hodgkin's lymphoma. Hematol Oncol Clin North Am 11:847–862PubMed

40.

Piris MA, Pezella F, Martinez-Montero JC, Orradre JL, Villuendas R, Sanchez-Beato M, Cuena R, Cruz MA, Martinez B, Garrido MC, Gatter K, Aiello A, Delia D, Giardini R, Rilke F (1994) P53 and bcl-2 expression in high-grade B-cell lymphomas: correlation with survival time. Br J Cancer 69:337–341PubMed

41.

Ichikawa A, Kinoshita T, Watanabe T, Kato H, Nagai H, Tsushita K, Saito H, Hotta T (1997) Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med 337:529–534

42.

Leroy K, Haioun C, Lepage E, Le Métayer N, Berger F, Labouyrie E, Meignin V, Petit B, Bastard C, Salles G Gisselbrecht C, Reyes F, Gaulard Ph (2002) P53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas. Ann Oncol 13:1108–1115

43.

Maartense E, Kramer MHH, Cessie le S, Kluin-Nelemans JC, Kluin PhM, Snijder S, Noordijk EM (2003) Lack of prognostic significance of BCL2 and p53 protein overexpression in elderly patients with diffuse large B-cell non-Hodgkin's lymphoma: results from a population-based non-Hodgkin's lymphoma registry. Leuk Lymphoma, in press

44.

Alizadeh AA, Eisen MB, Davis ER, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson Jr J, Lu L, Lewis DB, Tibshirani R, Sherloc, G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503–511PubMed

45.

Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RCT, Gaasenbeek M, Angelo M, Reich M, Pinkus GS, Ray TS, Koval MA, Last KW, Norton A, Lister TA, Mesirow J, Neuberg DS, Lander ES, Aster JC, Golub TR (2002) Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nature Med 8:68–74CrossRefPubMed

46.

Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink K, Smeland EB, Staudt LM (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N Engl J Med 346:1937–1947

47.

Maazen RWM van der, Noordijk EM, Thomas J, Raemaekers JMM, Meerwaldt JH (1998) Combined modality treatment is the treatment of choice for stage I/IE intermediate and high grade non-Hodgkin's lymphomas. Radiother Oncol 49:1-7CrossRefPubMed

48.

Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan ThM, LeBlanc M, Carlin S, Chase E, Fisher RI (1998) Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high grade non-Hodgkin's lymphoma. N Engl J Med 339:21–26PubMed

49.

Bonnet C, Fillet G, Mounier N, Thieblemont C, Fermé C, Quesnel B, Martin C, Blanc M, Conroy Th, Penny AM, Petrella T, Reyes F (2002) Radiotherapy is unnecessary in elderly patients with localized aggressive non-Hodgkin's lymphoma: results of the LNH 93–4 study. Ann Oncol 13 [Suppl 2]:A079

50.

Monfardini S, Zagonel V, Noordijk EM (1998) Lymphomas. Crit Rev Oncol Hematol 27:157–160CrossRefPubMed

51.

Zachariah B, Balducci L, Venkattaramanabalaji GV, Casey L, Greenberg HM, DelRegato JA (1997) Radiotherapy for cancer patients aged 80 and older: a study of effectiveness and side effects. Int J Radiat Oncol Biol Phys 39:1125–1129CrossRefPubMed

52.

Vose JM, Armitage JO, Weisenburger DD, Bierman PhJ, Sorensen S, Hutchins M, Moravec DF, Howe D, Dowling MD, Mailliard J, Steven Johnson P, Pevnick W, Packard WM, Okerbloom J, Thompson RF, Langdon Jr RM, Soori G, Peterson C (1988) The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol 6:1838–1844PubMed

53.

Sonneveld P, Michiels JJ (1990) Full dose chemotherapy in elderly patients with non-Hodgkin's lymphoma: a feasibility study using a mitoxantrone containing regimen. Br J Cancer 62:105–108PubMed

54.

O'Reilly SE, Connors JM, Howdle S, Hoskins P, Klasa R, Klimo P, Stuart DS (1993) In search of an optimal regimen for elderly patients with advanced-stage diffuse large-cell lymphoma: results of a phase II study of P/DOCE chemotherapy. J Clin Oncol 11:2250–2257PubMed

55.

Martelli M, Guglielmi C, Coluzzi S, Avvisati G, Amadori S, Giovannini M, Torromeo C, Mandelli F (1993) P-VABEC: a prospective study of a new weekly chemotherapy regimen for elderly aggressive non-Hodgkin's lymphoma. J Clin Oncol 11:2362–2369PubMed

56.

Bertini M, Freilone R, Vitolo U, Botto B, Pizzuti M, Gavarotti P, Levis A, Orlandi E, Orsucci L, Pini M, Rota Scalabrini D, Salvi F, Secondo V, Todeschini G, Viero P, Volta C, Resegotti L (1994) P-VEBEC: a new 8-weekly schedule with or without rG-CSF for elderly patients with aggressive non-Hodgkin's lymphoma (NHL). Ann Oncol 5:895–900PubMed

57.

Tirelli U, Zagonel V, Sorio R, Errante D, Talamini R, Carbone A, Monfardini S (1994) Mitoxantrone in combination with etoposide and prednimustine in patients older than 70 years with unfavorable non-Hodgkin's lymphoma: a prospective study in 52 patients. Semin Hematol 31 [Suppl 3]:13–22

58.

Guerci A, Lederlin P, Reyes F, Bordessoule D, Sebban C, Tilly H, Kerneis Y, Biron P, Gisselbrecht C, Herbrecht R, Coiffier B (1996) Effect of granulocyte colony-stimulating factor administration in elderly patients with aggressive non-Hodgkin's lymphoma treated with a pirarubicin-containing chemotherapy regimen. Ann Oncol 7:966–969

59.

Zinzani PL, Storti S, Zaccaria A, Moretti L, Magagnoli M, Pavone E, Gentilini P, Guardigni L, Gobbi M, Fattori PP, Falini B, Lauta VM, Bendandi M, Gherlinzoni F, De Renzo A, Zaja F, Mazza P, Volpe E, Bocchia M, Aitini E, Tabanelli M, Leone G, Tura S (1999) Elderly aggressive-histology non-Hodgkin's lymphoma: first-line VNCOP-B regimen experience on 350 patients. Blood 94:33–38PubMed

60.

Zinzani PL, Gherlinzoni F, Storti S, Zaccaria A, Pavone E, Moretti L, Gentilini P, Guardigni L, De Renzo A, Fattori PP, Falini B, Lauta VM, Mannin D, Zaja F, Mazza P, Volpe E, Lauria F, Aitini E, Ciccone F, Tani M, Stefoni V, Alinari L, Baccarini M, Tura S (2002) Randomized trial of 8-week versus 12-week VNCOP-B plus G-CSF regimens as front-line treatment in elderly aggressive non-Hodgkin's lymphoma patients. Ann Oncol 13:1364–1369

61.

Kouroukis CT, Browman GP, Esmail R, Meyer RM (2002) Chemotherapy for older patients with newly diagnosed advanced-stage, aggressive-histology non-Hodgkin lymphoma: a systematic review. Ann Intern Med 136:144–152

62.

Balducci L, Yates J (2000) General guidelines for the management of older patients with cancer. Oncology 14:221–227PubMed

63.

Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo PhA, Schiffer ChA, Smith ThJ, Somlo G, Wade JC, Wade III JL, Winn RJ, Wozniak AJ, Somerfield MR (2000) 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 18:3558–3585PubMed

64.

Zinzani PL, Pavone E, Storti S, Moretti L, Fattori PP, Guardigni L, Falini B, Gobbi M, Gentilini P, Lauta VM, Bendandi M, Gherlinzoni F, Magagnoli M, Venturi S, Aitini E, Tabanelli M, Leone G, Liso V, Tura S (1997) Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade nonHodgkin's lymphoma. Blood 89:3974–3979PubMed

65.

Ösby E, Hagberg H, Kvalöy S, Teerenhovi L, Anderson H, Cavallin-Stahl E, Holte H, Myhre J, Pertovaara H, Björkhom M (2003) CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim: results of a Nordic Lymphoma Group randomized trial. Blood 101:3840–3848CrossRefPubMed

66.

Doorduijn JK, Holt B van der, Buijt I, Hem van der KG, Imhoff van GW, Kramer MHH, Oers van MHJ, Ossenkoppele GJ, Schaafsme MR, Verdonck LF, Verhoef GEG, Steijaert MMC, Löwenberg B, Sonneveld P (2002) Prophylactic granulocyte-colony stimulating factor (G-CSF) added to CHOP in the treatment of elderly patients with aggressive non-Hodgkin's lymphoma (NHL). Final results of a multicenter phase 3 study. Ann Oncol 13 [Suppl 2]:A083

67.

Pfreundschuh M, Trümper L, Kloess M, Schmitz N, Glass B, Schmits R, Engert A, Rudolph C, Illiger J, Hossfeld D, Loeffler M (2002) 2-Weekly CHOP (CHOP-14): the new standard regimen for patients with aggressive non-Hodgkin's lymphoma (NHL) >60 years of age. Ann Oncol 13 [Suppl 2]:A081

68.

Coiffier B, Lepage E, Brière J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Neste van den E, Salles G, Gaulard Ph, Reyes F, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 346:235–242PubMed

69.

Mounier N, Briere J, Gisselbrecht C, Gaulard PH, Lederlin P, Sebban C, Bosly A, Morel P, Tilly H, Bouabdallah R, Reyes F, Coiffier B (2002) Rituximab plus CHOP (R-CHOP) in the treatment of elderly patients with diffuse large B-cell lymphoma (DLBCL) overcomes Bcl2-associated chemotherapy resistance. Blood 100:A603

70.

Pettengell R, Linch D (2003) Position paper on the therapeutic use of rituximab in CD20-positive diffuse large B-cell non-Hodgkin's lymphoma. Br J Haematol 121:44–48PubMed

71.

Cheson BD (2003) Radioimmunotherapy of non-Hodgkin lymphomas. Blood 101:391–398CrossRefPubMed

72.

Rijke JM de, Schouten LJ, Schouten HC, Jager JJ, Koppejan AG, Brandt van den PA (1996) Age-specific differences in the diagnostics and treatment of cancer patients aged 50 years and older in the province of Limburg, the Netherlands. Ann Oncol 7:677–685PubMed

73.

Horning SJ (1993) Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 20 [Suppl 5]:S75-S88

74.

Nathwani BN, Harris NL, Weisenburger D, Isaacson PG, Piris MA, Berger F, Muller-Hermelink HK, Swerdlow SH (2001) Follicular lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon, pp 162–167

75.

Peters FPJ, Lalisang RI, Fickers MMF, Erdkamp FLG, Wils JAJM, Houben SJG, Wals J, Schouten HC (2001) Treatment of elderly patients with intermediate- and high-grade non-Hodgkin's lymphoma: a retrospective population-based study. Ann Hematol 80:155–159CrossRefPubMed

76.

Neilly IJ, Ogston M, Bennett B, Dawson AA (1995) High grade non-Hodgkin's lymphoma in the elderly—12 year experience in the Grampian region of Scotland. Hematol Oncol 13:99–106PubMed

77.

Armitage JO, Potter JF (1984) Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly. J Am Geriatr Soc 32:269–273PubMed

78.

Dixon DO, Neilan B, Jones SE, Lipschitz DA, Miller ThP, Grzea PN, Wilson HE (1986) Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol 4:295–305PubMed

79.

Coiffier B (1994) What treatment for elderly patients with aggressive lymphoma? Ann Oncol 5:873–875PubMed

80.

Naeim A, Reuben D (2001) Geriatric syndromes and assessment in older cancer patients. Oncology 15:1567–1580PubMed

81.

Serraino D, Fratino L, Zagonel V, for the GIOGer Study Group (2001) Prevalence of functional disability among elderly patients with cancer. Crit Rev Oncol Hematol 39:269–273CrossRefPubMed

82.

Zagonel V (2001) Importance of a comprehensive geriatric assessment in older cancer patients. Eur J Cancer 37 [Suppl 7]:S229–S233

83.

Stuck AE, Siu AL, Wieland GD (1993) Comprehensive geriatric assessment: a meta-analysis of controlled trials. Lancet 342:1032–1036PubMed

84.

Cohen HJ, Feussner JR, Weinberger M, Carnes M, Hamdy RC, Hsieh F, Phibbs C, Lavori Ph (2002) A controlled trial of inpatient and outpatient geriatric evaluation and management. N Engl J Med 346:905–912CrossRefPubMed

85.

Ingram SS, Seo PH, Martell RE, Clipp EC, Doyle ME, Montana GS, Cohen HJ (2002) Comprehensive assessment of the elderly cancer patient: the feasibility of self-report methodology. J Clin Oncol 20:770–775CrossRefPubMed

86.

Freyer G, Le Rol A, Weber B,Provencal J, Ganem G, Jacquin J, Lavau-Denes S, Gisserot O, Flesch M, Paraiso D (2002) Geriatric evaluation and feasibility of platin-based first-line chemotherapy in elderly patients with advanced ovarian cancer. Proc ASCO 2002:A1432

87.

Zagonel V, Fratino L, Piselli P, Milan I, La Conca G, Serraino D, Monfardini S (2002) The comprehensive geriatric assessment predicts mortality among elderly cancer patients. Proc ASCO 2002:A1458

88.

Colussi AM, Mazzer L, Candotto D, De Biasi M, De Lorenzi L, Pin I, Pusiol N, Romanin C, Zamattio V (2001) The elderly cancer patient: a nursing perspective. Crit Rev Oncol Hematol 39:235–245CrossRefPubMed

89.

Lachs MS, Feinstein AR, Cooney Jr. LM, Drickamer MA, Marottoli RA, Pannill FC, Tinetti ME (1990) A simple procedure for general screening for functional disability in elderly patients. Ann Intern Med 112:699–706PubMed

90.

Folstein MF, Folstein SE, McHugh PR (1975) Mini mental state. A practical method for grading the cognitive state of patients for the clinicians. J Psychiatr Res 12:189–198PubMed

91.

Brink TL, Yesavage JA, Lum O, Hevesuma PH, Adey M, Rose TL (1982) Screening test for geriatric depression. Clin Gerontol 1:37–44

92.

Katz S, Akpom CA (1976) A measure of primary sociological function. Int J Health Serv 6:493–507PubMed

93.

Lawton MP, Moss M, Fulcomer M, Kleban MH (1982) A research and service oriented multilevel assessment instrument. J Gerontol 37:91–99PubMed

94.

Extermann M (1999) Assessment of the older cancer patient. In: Perry MC (ed) American Society of Clinical Oncology 1999 educational book. Lippincott Williams & Wilkins, Baltimore, pp 353–360

Titel: Non-Hodgkin's lymphoma in the elderly
A review with emphasis on elderly patients, geriatric assessment, and future perspectives
verfasst von: E. Maartense
H. C. Kluin-Nelemans
E. M. Noordijk
Publikationsdatum: 01.11.2003
Verlag: Springer-Verlag
Erschienen in: Annals of Hematology / Ausgabe 11/2003
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-003-0722-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Non-Hodgkin's lymphoma in the elderly

A review with emphasis on elderly patients, geriatric assessment, and future perspectives

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2003

Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors

Subtotal splenectomy for the treatment of chronic lymphocytic leukemia

November 2003

Immunosuppressive therapy with antithymocyte globulin and cyclosporine for prolonged marrow failure after hemophagocytic syndrome

Life-threatening thrombotic thrombocytopenic purpura (TTP) in a patient with sickle cell-hemoglobin C disease

Mutations of the 5′ noncoding region of the BCL-6 gene in primary bone lymphomas

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin